GEN Exclusives

More »

GEN News Highlights

More »
Feb 17, 2009

EMBL Licenses Tripos' Software to Advance Drug Discovery

EMBL Licenses Tripos' Software to Advance Drug Discovery

EMBL to advance drug discovery research with Tropos' software

  • The European Molecular Biology Laboratory (EMBL) signed an agreement to license Tripos' Themis and Surflex-Dock software to advance its drug discovery efforts within chemical biology.

    The software will be used to enable small molecule development among research groups in the Chemical Biology Core Facility, a three-way collaboration between the EMBL, the German Cancer Research Center, and the University of Heidelberg.

    The EMBL says that in studies to assess Surflex-Dock, the software yielded promising compound candidates for testing in about two days.

    It docked five million structures of the research institute's virtual database of commercially available compounds into a binding site of a project's receptor structure.

    Additionally, in the first experiments with Themis, the software provided new chemical ideas that would contribute to drug discovery projects, adds Joe Lewis, Ph.D, head of the facility.ADNFCR-2184-ID-19031149-ADNFCR



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?